Search results for "Tensin"

showing 10 items of 425 documents

SYMPATHETIC NERVOUS SYSTEM AND BLOOD-PRESSURE CONTROL IN ESSENTIAL HYPERTENSION

1978

Abstract In normotensive subjects an inverse correlation was observed between an index of sympathetic nervous activity (the plasma-noradrenaline concentration during physical exercise) and reactivity to exogenous noradrenaline. This relationship was invariably disturbed in age-matched patients with essential hypertension. Multiple-regression analysis revealed a highly significant correlation between the combination of both factors and the height of mean arterial blood-pressure ( r =0·91). The findings suggest that sympathetic nervous activity and pressor response to noradrenaline together form an important determinant of the arterial blood-pressure level. An inverse relationship could be de…

AdultMaleBlood pressure controlmedicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemRestPhysical ExertionBlood PressurePhysical exerciseEssential hypertensionNorepinephrineInternal medicineReninHumansMedicineInverse correlationbusiness.industryAngiotensin IIGeneral MedicineMiddle Agedmedicine.diseaseAngiotensin IIHormonesmedicine.anatomical_structureEndocrinologyPressor responsePathophysiology of hypertensionHypertensionRegression AnalysisFemalebusinessThe Lancet
researchProduct

Sublingual administration of captopril versus nitroglycerin in patients with severe congestive heart failure.

1990

Angiotensin-converting enzyme inhibition has proven to be a successful approach for the long-term treatment of patients with congestive heart failure. This investigation compared the acute hemodynamic changes after sublingual administration of the angiotensin-converting enzyme inhibitor captopril with those after nitroglycerin. A total of 24 patients with severe left heart failure (New York Heart Association classes III and IV) were given 25 mg captopril and 0.8 mg nitroglycerin sublingually in this randomized, cross-over study. Hemodynamic monitoring revealed a clear improvement in pre- and afterload parameters for both drugs (P less than 0.01 and P less than 0.001), while captopril induce…

AdultMaleCaptoprilCardiac indexAdministration SublingualHemodynamicsSublingual administrationNitroglycerinAfterloadmedicineHumanscardiovascular diseasesAgedHeart Failurebiologybusiness.industryHemodynamicsCaptoprilAngiotensin-converting enzymeStroke volumeMiddle Agedmedicine.diseaseAnesthesiaHeart failurebiology.proteinFemaleVascular ResistanceCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologymedicine.drugInternational journal of cardiology
researchProduct

Angiotensin type 2 receptor is important in the normal development of the ureter

1999

In humans, the actions of angiotensin II are transduced through the AT1 and AT2 receptors which have recently been implicated in renal organogenesis. Polymorphisms in the human angiotensin II receptor genes have been linked to cardiovascular and nephrological disorders. In this study we evaluated 35 patients with either primary obstructive megaureter or posterior urethral valves. Each was genotyped for the A1166 AT1 polymorphism and the recently described A-1332G AT2 transition. The incidence of these genetic variants was also evaluated in normal controls without any ultrasonographic urological abnormalities. Similar to our previous findings in congenital urological abnormalities, the AT1 r…

AdultMaleNephrologymedicine.medical_specialtyAngiotensin receptorAdolescentGenotypeMegaureterUrologyReceptor Angiotensin Type 2Receptor Angiotensin Type 1White PeopleGene FrequencyUrethraInternal medicineUrethral DiseasesmedicineHumansChildReceptorReceptors AngiotensinAngiotensin II receptor type 1business.industryCase-control studyInfantmedicine.diseaseAngiotensin IIEndocrinologyNephrologyChild PreschoolPediatrics Perinatology and Child HealthGene polymorphismUreterbusinesshormones hormone substitutes and hormone antagonistsUreteral ObstructionPediatric Nephrology
researchProduct

The DD genotype of the angiotensin converting enzyme gene independently associates with CMR-derived abnormal microvascular perfusion in patients with…

2009

Abstract Introduction The role of the angiotensin converting enzyme (ACE) gene on the result of thrombolysis at the microvascular level has not been addressed so far. We analyzed the implications of the insertion/deletion (I/D) polymorphism of the ACE gene on the presence of abnormal cardiovascular magnetic resonance (CMR)-derived microvascular perfusion after ST-segment elevation myocardial infarction (STEMI). Materials and Methods We studied 105 patients with a first anterior STEMI treated with thrombolytic agents and an open left anterior descending artery. Microvascular perfusion was assessed using first-pass perfusion CMR at 7 ±1 days. CMR studies were repeated 184 ± 11 days after STEM…

AdultMaleRiskmedicine.medical_specialtyGenotypemedicine.medical_treatmentMyocardial InfarctionPeptidyl-Dipeptidase AFibrinolytic AgentsInternal medicineHumansMedicineMyocardial infarctionAgedPolymorphism GeneticEjection fractionbiologybusiness.industryMicrocirculationAngiotensin-converting enzymeHematologyThrombolysisMiddle Agedmedicine.diseaseMagnetic Resonance ImagingGenotype frequencyTreatment Outcomemedicine.anatomical_structurebiology.proteinCardiologyFemalebusinessPerfusionGene DeletionTIMIArteryThrombosis Research
researchProduct

Rationale for and design of the CREATIVE-AF trial: randomized, double-blind, placebo-controlled, crossover study of the effect of irbesartan on oxida…

2008

Background and objective: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Recent studies suggest there is an angiotensin II-dependent increase in adhesion molecules and oxidative stress parameters during AF. These alterations appear to contribute to inflammatory and prothrombotic changes in the atrial endocardium (‘endocardial remodelling’), suggesting that patients with increased levels of these factors might be at risk of thromboembolic events. The purpose of the CREATIVE-AF (Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients with Persistent Atrial Fibrillation) trial is to prove the principle concept that blockade of angiotensin II type 1 r…

AdultMalemedicine.medical_specialtyAdolescentEndpoint DeterminationTetrazolesmedicine.disease_causeYoung AdultIrbesartanVon Willebrand factorDouble-Blind MethodInternal medicineAtrial FibrillationmedicineHumansPharmacology (medical)Cell adhesionAgedCross-Over StudiesbiologyCell adhesion moleculebusiness.industryPatient SelectionBiphenyl CompoundsAtrial fibrillationGeneral MedicineIrbesartanMiddle Agedmedicine.diseaseAngiotensin IICrossover studyOxidative StressData Interpretation StatisticalSample SizeCardiologybiology.proteinFemalebusinessAngiotensin II Type 1 Receptor BlockersCell Adhesion MoleculesOxidative stressBiomarkersmedicine.drugClinical drug investigation
researchProduct

Inefficient arterial hypertension control in patients with metabolic syndrome and its link to renin-angiotensin-aldosterone system polymorphisms.

2011

There is evidence that uncontrolled arterial hypertension (AHT) in patients with metabolic syndrome (MS) increases cardiovascular risks. The renin-angiotensin-aldosterone system (RAAS) and its polymorphisms apparently confer a genetic risk for uncontrolled AHT. This study aims to investigate the influence of RAAS polymorphisms on AHT control in patients diagnosed with MS. This is a two-stage population-based nested case-control pilot study (n=1514). We differentiated between MS-diagnosed patients and non-MS patients (ATP-III criteria) and selected those individuals diagnosed with AHT from each group (n=161 and n=156, respectively). Those who successfully controlled their AHT (controls) and …

AdultMalemedicine.medical_specialtyAdolescentPhysiologyPopulationPilot ProjectsGastroenterologyPolymorphism Single NucleotideRenin-Angiotensin SystemPolymorphism (computer science)Internal medicineRenin–angiotensin systemInternal MedicinemedicineHumanseducationAgedAged 80 and overMetabolic Syndromeeducation.field_of_studybusiness.industryConfoundingOdds ratioMiddle Agedmedicine.diseaseEndocrinologyBlood pressureCase-Control StudiesHypertensionFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBody mass indexHypertension research : official journal of the Japanese Society of Hypertension
researchProduct

How ineffective hypertension control in subjects treated with angiotensin-converting enzyme inhibitors is related to polymorphisms in the renin-angio…

2009

Abstract Purpose To investigate how genetic polymorphisms of the renin-angiotensin-aldosterone system (RAAS) influence hypertension (HT) control with angiotensin-converting enzyme inhibitor drugs (ACEI). Methods A case–control, cross-sectional population-based nested study (n = 1514) included hypertensive patients treated with ACEI drugs, either alone or with other antihypertensive drugs. We differentiated between those who did not control their HT (cases) with those who did (controls). Each group's characteristics were compared to determine the risk of non-controlled HT associated with RAAS polymorphisms by adjusting for different variables. Results rs11571074 obtained an ORa of 5.26 for T…

AdultMalemedicine.medical_specialtyAdolescentPopulationPharmaceutical ScienceAngiotensin-Converting Enzyme InhibitorsPharmacologyYoung AdultPolymorphism (computer science)Internal medicineRenin–angiotensin systemGenotypemedicineHumanseducationAgedAged 80 and overeducation.field_of_studyPolymorphism GeneticHypertension controlbiologybusiness.industryCase-control studyAngiotensin-converting enzymeMiddle AgedEndocrinologyCross-Sectional StudiesCase-Control StudiesACE inhibitorHypertensionbiology.proteinFemalebusinessmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

2001

To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension.A multicenter, randomised, double-blind parallel group study was performed in Finland, France, the Netherlands, Spain and Sweden. Three-hundred-and-ninety-five men and women in the age range 20-80 years with primary hypertension were randomised to an 8-week double-blind treatment period with either candesartan cilexetil 8-16 mg or enalapril 10-20 mg once daily, with forced dose titration after 4 weeks. Non-invasive ambulatory blood pressure…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureTime Factorsmedicine.medical_treatmentDiastoleTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood PressureAngiotensin Receptor AntagonistsDouble-Blind MethodEnalaprilHeart RateInternal medicineInternal MedicinemedicineHumansProdrugsEnalaprilAntihypertensive AgentsAgedAged 80 and overChemotherapybiologybusiness.industryBiphenyl CompoundsAngiotensin-converting enzymeGeneral MedicineMiddle AgedAngiotensin IICandesartanEndocrinologyTherapeutic EquivalencyACE inhibitorHypertensionbiology.proteinCardiologyBenzimidazolesFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct

Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment.

2013

The objective of the present study was to assess the regression of left ventricular hypertrophy (LVH) during antihypertensive treatment, and its relationship with the changes in microalbuminuria.One hundred and sixty-eight previously untreated patients with echocardiographic LVH, 46 (27%) with microalbuminuria, were followed during a median period of 13 months (range 6-23 months) and treated with lifestyle changes and antihypertensive drugs. Twenty-four-hour ambulatory blood pressure monitoring, echocardiography and urinary albumin excretion were assessed at the beginning and at the end of the study period.Left ventricular mass index (LVMI) was reduced from 137 [interquartile interval (IQI)…

AdultMalemedicine.medical_specialtyAngiotensin receptorAmbulatory blood pressurePhysiologyHeart VentriclesBlood PressureLeft ventricular hypertrophyExcretionInterquartile rangeRisk FactorsInternal medicineAlbuminsInternal MedicineMedicineAlbuminuriaHumanscardiovascular diseasesAntihypertensive Agentsbusiness.industryBlood Pressure Monitoring AmbulatoryMiddle Agedmedicine.diseaseRegressionBlood pressureTreatment OutcomeEchocardiographyHypertensionCardiologyMicroalbuminuriaFemaleHypertrophy Left VentricularCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateJournal of hypertension
researchProduct

Sexual dysfunction in hypertensive patients treated with losartan.

2001

ABSTRACT Background Impaired erectile function in men is a component of the dysmetabolic syndrome of high blood pressure as well as a sequela of antihypertensive therapy. This prospective interventional study in men with uncontrolled hypertension (blood pressure ≥ 140/90 mm Hg) used a survey instrument to assay sexual dysfunction before and after therapy with losartan. Methods We evaluated the influence of a 12-week therapy with losartan in 82 hypertensive subjects with (n = 82) and without (n = 82) a diagnosis of erectile dysfunction using a self-administered questionnaire validated in another 60 subjects with hypertension. Results: From an initial sample of 323 hypertensive men and women,…

AdultMalemedicine.medical_specialtyAngiotensin-Converting Enzyme InhibitorsLosartanInternal medicinemedicineHumansProspective StudiesSexual Dysfunctions PsychologicalProspective cohort studyDiureticsAntihypertensive AgentsAgedbusiness.industrySequelaGeneral MedicineMiddle Agedmedicine.diseaseSurgeryRegimenBlood pressureErectile dysfunctionLosartanSexual dysfunctionHypertensionFemalemedicine.symptombusinessSexual functionmedicine.drugThe American journal of the medical sciences
researchProduct